BioCentury | Aug 28, 2020

Biotech may have side-stepped CFIUS’ worst case scenario

So far, biotech has avoided the nightmare scenario in which almost any private company seeking foreign investment would come under government scrutiny. Recently proposed legislation could inject additional...
BioCentury | Jul 14, 2020

Three biotechs step up to the IPO plate following Nkarta’s debut

Berkeley Lights, ALX and Pandion are next in line for NASDAQ debuts as massive inflows into the sector continue to prompt upsized offerings, and double- to triple-digit aftermarket moves. If each biotech priced at the...
BioCentury | Jun 30, 2020

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

Temasek takes stake in BioNTech BioNTech SE (NASDAQ:BNTX) raised about $250 million from Temasek and other undisclosed investors in a private placement comprising $139 million in stock and $112 million in convertible notes. The biotech...
BioCentury | May 30, 2020
Politics, Policy & Law

Proposed changes to CFIUS rules would ensnare more Chinese-backed U.S. biotechs

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could increase mandatory filings for companies with investors from countries subject...
BioCentury | May 30, 2020
Translation in Brief

Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more

Brain cancer CAR T therapy A McMaster University and University of Toronto team revealed in a Cell Stem Cell paper proof-of-concept data for Empirica Therapeutics’ lead product eCAR-133, a CAR T cell therapy targeting PROM1....
BioCentury | Apr 1, 2020

Pandion’s immune-regulating platform attracts $80M B round

Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Feb 15, 2020
Politics, Policy & Law

With Treasury’s CFIUS rules in effect, eyes on Commerce definitions

Although the finalized rules governing Treasury Department’s review of foreign investments in U.S. companies went into effect Thursday, ambiguity from the Commerce Department on what biotechnologies could merit mandatory filings means lingering uncertainty for biopharma....
BioCentury | Jan 30, 2020
Distillery Therapeutics

IL1RL1 in Treg cells as a lung cancer target

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting IL1RL1, which signals in response to IL-33 binding, in Treg cells could treat lung cancer. In single-cell RNA sequencing analyses of CD4 + T cells from the lymph...
BioCentury | Jan 18, 2020
Politics, Policy & Law

Final reg reduces numbers of biopharma companies subject to CFIUS reviews

Final regulations implementing the Foreign Investment Risk Review Modernization Act of 2018 released on Jan. 14 represent a partial victory for the biopharma industry, but the process is still certain to cast a cloud over...
Items per page:
1 - 10 of 185